Kezar Life Sciences Inc (NASDAQ:KZR) – Analysts at William Blair issued their FY2020 EPS estimates for Kezar Life Sciences in a note issued to investors on Tuesday, March 12th. William Blair analyst M. Phipps anticipates that the company will earn ($2.39) per share for the year. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Kezar Life Sciences’ FY2021 earnings at ($2.34) EPS and FY2022 earnings at ($2.42) EPS.
Other research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Kezar Life Sciences from a “hold” rating to a “buy” rating and set a $29.00 price target for the company in a report on Tuesday, November 20th. ValuEngine downgraded shares of Kezar Life Sciences from a “buy” rating to a “hold” rating in a report on Thursday, December 13th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $27.33.
Several large investors have recently modified their holdings of the company. FMR LLC increased its position in shares of Kezar Life Sciences by 12.6% during the fourth quarter. FMR LLC now owns 2,849,233 shares of the company’s stock worth $67,242,000 after acquiring an additional 318,852 shares during the period. EcoR1 Capital LLC increased its position in shares of Kezar Life Sciences by 1.3% during the third quarter. EcoR1 Capital LLC now owns 1,288,198 shares of the company’s stock worth $27,580,000 after acquiring an additional 16,000 shares during the period. BB Biotech AG purchased a new position in shares of Kezar Life Sciences during the fourth quarter worth approximately $19,315,000. BlackRock Inc. increased its position in shares of Kezar Life Sciences by 1.9% during the fourth quarter. BlackRock Inc. now owns 245,932 shares of the company’s stock worth $5,804,000 after acquiring an additional 4,486 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Kezar Life Sciences by 126.7% during the fourth quarter. Geode Capital Management LLC now owns 58,046 shares of the company’s stock worth $1,369,000 after acquiring an additional 32,441 shares during the period. 48.89% of the stock is currently owned by institutional investors and hedge funds.
About Kezar Life Sciences
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Featured Article: Penny Stocks
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.